Physician profile
James M May
NPI 1396727780
$983.33
in general payments reported to CMS, 2019-2025
13 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Geriatric Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $14.82 · 2023: $49.75 · 2024: $364 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $168.55 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $159.35 | 2023-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $143.93 | 2024-2025 | Rexulti |
| Lundbeck LLC | $118.74 | 2023-2025 | Rexulti |
| Allergan, INC. | $98.85 | 2019-2020 | |
| Alkermes, INC. | $93.63 | 2023-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $64.16 | 2024-2025 | Trintellix |
| Biomerieux INC | $50.74 | 2025 | Filmarray Torch Module |
| Vanda Pharmaceuticals INC. | $34.30 | 2019-2024 | Fanapt |
| Tris Pharma INC | $15.34 | 2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $12.67 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.98 | 2019 | |
| Shire North American Group INC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.